Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Labcor Laboratorios Ltda currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner and is being processed within 1 distinct art unit. This indicates a very concentrated prosecution effort, where the company's current patent goals are focused on a specific technical classification and a single point of review at the patent office.
The busiest examiner for the portfolio is PENNINGTON, KATIE LEIGH, who is responsible for 1 busiest examiner pending office action. Because this examiner handles the only 1 pending office action for the company, the prosecution strategy must be highly tailored to this individual's specific requirements and the standards of the 1 distinct art unit involved. Practitioners should prioritize understanding the examiner's past actions and preferences, as there are no other active cases in the portfolio to provide broader context or alternative routes to allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688672 | METHOD FOR PRODUCING PRESERVED COLLAGENOUS CONNECTIVE TISSUE, COLLAGENOUS CONNECTIVE TISSUE, USES THEREOF AND KIT FOR IMPLANT IN TISSUES | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688672 | METHOD FOR PRODUCING PRESERVED COLLAGENOUS CONNECTIVE TISSUE, COLLAGENOUS CONNECTIVE TISSUE, USES THEREOF AND KIT FOR IMPLANT IN TISSUES | PENNINGTON, KATIE LEIGH | 1634 | §103§112DP | Non-Final OA | — | Pending | Mar 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLabcor Laboratorios Ltda has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katie Leigh Pennington has the most, with 1 of Labcor Laboratorios Ltda's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
